Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp. > Prev Biov requested cto now its osc issuing it, losing faith
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(83)
•••
Comment by Humaniston May 17, 2024 9:43am
32 Views
Post# 36045185

RE:Prev Biov requested cto now its osc issuing it, losing faith

RE:Prev Biov requested cto now its osc issuing it, losing faithSORRY FOR MY TYPOS!  
I MEANT TO SAY , MY TRUST IN THIS BEHAVIOUR HAS CHANGED.  SOMTHING IS QUESTIONABLE HERE.. 

Humanist wrote: now i feel differently after osc issued it due to them failing to file. why have they failed they had enough  time unless somthing is fishy..l my trust in this behaviour has changed. I hope biov can clear this up and give us a definite date. if thye don't we'rein trouble . i really trusted the company before.. 

what in the world is going on... 
glta


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities